{"nctId":"NCT00594100","briefTitle":"GORE Embolic Protection With Reverse Flow","startDateStruct":{"date":"2006-07"},"conditions":["Carotid Artery Stenosis"],"count":245,"armGroups":[{"label":"GFRS Pivotal Subjects","type":"EXPERIMENTAL","interventionNames":["Device: GORE Flow Reversal System (GFRS)"]}],"interventions":[{"name":"GORE Flow Reversal System (GFRS)","otherNames":["Gore Neuro Protection System"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Carotid stenosis requiring revascularization and indicating either symptomatic status, with carotid stenosis ≥ 50% OR asymptomatic status with carotid stenosis ≥ 80%\n* Target lesion is located in one of the following:(a) internal carotid artery (ICA) (b) bifurcation (c) common carotid artery (CCA) proximal to the bifurcation\n* At Anatomic risk for adverse events from CEA (e.g. restenosis after a prior CEA) OR at Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)\n\nExclusion Criteria:\n\n* Recent surgical procedure within 30 days before or after the stent procedure\n* Uncontrolled sensitivity to contrast media\n* Renal Insufficiency\n* Recent evolving, acute stroke within 21 days of study evaluation\n* Myocardial infarction within 72 hours prior to stent procedure\n* History of a prior major ipsilateral stroke with residual neurological deficits likely to confound the neurological assessments (e.g., NIHSS)\n* Neurological deficits not due to stroke likely to confound the neurological assessments (e.g., NIHSS)\n\nAngiographic Exclusion Criteria:\n\n* Isolated ipsilateral hemisphere leading to subject intolerance to reverse flow\n* Total occlusion of the ipsilateral carotid artery\n* Pre-existing stent in the ipsilateral carotid artery OR the contralateral carotid artery that extends into the aortic arch\n* Presence of a filling defect, thrombus, occlusion or \"string sign\" in the target vessel\n* Severe lesion calcification restricting stent deployment\n* Carotid stenosis located distal to target stenosis that is more severe than target stenosis\n* \\> 50% stenosis of the CCA proximal to target vessel\n* Known mobile plaque in the aortic arch","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite Major Adverse Event (MAE) Rate","description":"Number of participants with one or more Major Adverse Event (death, stroke, myocardial infarction, and/or transient ischemic attack (TIA)) through the 30-day follow-up (non-hierarchical; MAE adjudicated by independent Clinical Events Committee)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Flow Reversal System Technical Success","description":"Number of participants with Technical Success using the GORE Flow Reversal System (system deployed and utilized during stenting procedure)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"236","spread":null}]}]}]},{"type":"SECONDARY","title":"Flow Reversal System Success","description":"Number of participants where the GORE Flow Reversal System was delivered, placed, reverse flow was established, and the balloon sheath and wire retrieved as outlined in the Instructions for Use without causing any adverse events during the procedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"233","spread":null}]}]}]},{"type":"SECONDARY","title":"Stent Success","description":"Number of participants where the FDA-approved stent was successfully delivered, deployed,and delivery system removed with an attainment of \\< 50% residual stenosis following stent placement, as assessed by the angiographic core laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"228","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Success","description":"Number of participants with Flow Reversal System and Stent Success in the absence of death, emergency endarterectomy, repeat percutaneous transluminal angioplasty (PTA)/thrombolysis of the target vessel, stroke, or myocardial infarction (MI), as determined by the Clinical Events Committee (CEC).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null}]}]}]},{"type":"SECONDARY","title":"Patency at 30 Days","description":"Number of participants with less than 50% restenosis as determined by carotid duplex ultrasound core laboratory at 30 days post-procedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":245},"commonTop":["Hypotension","Other (Other)","Hypertension","Pain (Head, Neck)","Other (Neurologic)"]}}}